Counihan et al. 21 used chemoproteomics-enabled covalent ligand screening to reveal that ALDH3A1 may be a new therapeutic target for lung cancer and that ALDH3A1 inhibitors damage the pathogenicity of lung cancer in cells with high expression of ALDH3A1. Here, ALDH3A1 is linked to lung carcinoma.